Jazz Pharmaceuticals Announces Promising Phase 4 Data for Xywav® in Treating Narcolepsy and Idiopathic Hypersomnia at World Sleep and Psych Congresses
Jazz Pharmaceuticals plc announced promising Phase 4 data for Xywav® in treating narcolepsy and idiopathic hypersomnia. The findings, presented at World Sleep 2025 and the 38th annual Psych Congress, demonstrated the treatment's effectiveness in reducing excessive daytime sleepiness and improving sleep measures, including fewer awakenings and decreased wake after sleep onset. The data was derived from the DUET trial, a prospective, single-arm, open-label study.
Jazz Pharmaceuticals plc has announced the presentation of new Phase 4 data and real-world evidence showcasing the effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in treating adults with narcolepsy or idiopathic hypersomnia. These findings were shared at World Sleep 2025 in Singapore and the 38th annual Psych Congress in San Diego. The data from the DUET trial, a prospective, single-arm, open-label study, highlighted the treatment’s impact on excessive daytime sleepiness, polysomnography parameters, and functional outcomes. Notably, the study showed that Xywav treatment led to fewer awakenings and decreased wake after sleep onset in participants with narcolepsy and idiopathic hypersomnia, indicating improved sleep measures. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: SF78002) on September 22, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
